FDA approves Alcon's Simbrinza for glaucoma and ocular hypertension

04/22/2013 | RTT News

Novartis unit Alcon obtained approval from the FDA to market Simbrinza Suspension, a fixed-dose combination of Brinzolamide and Brimonidine Tartrate, for the reduction of elevated intraocular pressure in patients suffering from primary open-angle glaucoma or ocular hypertension. The approval makes Simbrinza the first fixed-dose glaucoma combo treatment in the U.S. that doesn't contain a beta blocker.

View Full Article in:

RTT News

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR